PCN227 A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.423
https://www.valueinhealthjournal.com/article/S1098-3015(19)32801-3/fulltext
Section Title :
Section Order : 10352
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32801-3&doi=10.1016/j.jval.2019.09.423
HEOR Topics :
Tags :
Regions :